PasireotideHormone TherapySafety Rating 8/10
Primary research areaCushing's disease
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range0.3-0.9 mg SC twice daily; 40-60 mg IM monthly
AdministrationSubcutaneous or IM injection
Safety8/10 · FDA-approved (Signifor)
NCAA D1Not listed
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Pasireotide
Mechanism of action
Multi-receptor somatostatin analog (SSTR1/2/3/5); suppresses ACTH from pituitary corticotrophs
Safety profile
Hyperglycemia (major concern), GI effects, bradycardia, cholelithiasis · Approved for Cushing's; hyperglycemia common (expected with mechanism); GI side effects
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Pasireotide below your target.
Related pages